Published in Arthritis Rheum on December 15, 2004
Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol (2007) 1.88
The Hopkins Lupus Pregnancy Center: ten key issues in management. Rheum Dis Clin North Am (2007) 0.99
Severe relapse of Wegener's granulomatosis during the early postpartum period. Ann Rheum Dis (2006) 0.95
Cytokine networks in systemic lupus erythematosus. J Biomed Biotechnol (2010) 0.93
Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus. J Biomed Biotechnol (2010) 0.92
Benefit of pregnancy in inflammatory arthritis. Ann Rheum Dis (2005) 0.92
Understanding and Managing Pregnancy in Patients with Lupus. Autoimmune Dis (2015) 0.89
New-onset systemic lupus erythematosus during pregnancy. Clin Rheumatol (2013) 0.86
Association of Insulin Resistance with Serum Interleukin-6 and TNF-α Levels During Normal Pregnancy. Biomark Insights (2011) 0.85
Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis (2005) 0.85
Down-regulated NOD2 by immunosuppressants in peripheral blood cells in patients with SLE reduces the muramyl dipeptide-induced IL-10 production. PLoS One (2011) 0.83
Effect of pregnancy on serum cytokines in SLE patients. Arthritis Res Ther (2012) 0.81
Pregnancy and the Immune System: General Overview and the Gastroenterological Perspective. Dig Dis Sci (2015) 0.80
[Rare autoimmune rheumatic illnesses during pregnancy. Systemic sclerosis, polymyositis/dermatomyositis and vasculitis]. Z Rheumatol (2006) 0.75
Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis (2010) 10.97
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
Identification of a central role for complement in osteoarthritis. Nat Med (2011) 3.11
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis (2010) 2.91
Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol (2011) 2.45
Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. Arthritis Rheum (2002) 2.23
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum (2012) 2.23
Diagnosis and therapy of antiphospholipid syndrome. Pol Arch Med Wewn (2015) 2.06
Autophagy in human health and disease. N Engl J Med (2013) 2.04
Anti-thyroid antibodies and thyroid dysfunction in rheumatoid arthritis: prevalence and clinical value. Autoimmunity (2008) 1.90
Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther (2009) 1.87
The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. Clin Rheumatol (2014) 1.87
Gout: why is this curable disease so seldom cured? Ann Rheum Dis (2012) 1.84
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood (2011) 1.79
Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum (2007) 1.78
Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol (2010) 1.78
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) (2009) 1.76
How psychological stress via hormones and nerve fibers may exacerbate rheumatoid arthritis. Arthritis Rheum (2005) 1.70
Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol (2010) 1.64
Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum (2008) 1.51
Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. Ann Rheum Dis (2009) 1.48
The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev (2011) 1.47
Serum amyloid-A in Behçet's disease. Clin Rheumatol (2014) 1.47
Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol (2009) 1.44
Neuroendocrine immune mechanisms in rheumatic diseases. Trends Immunol (2002) 1.44
Long-term high-level exercise promotes muscle reinnervation with age. J Neuropathol Exp Neurol (2014) 1.40
Estrogens and autoimmune diseases. Ann N Y Acad Sci (2006) 1.37
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol (2007) 1.34
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci (2006) 1.32
Epidemiology of chronic musculoskeletal pain. Best Pract Res Clin Rheumatol (2011) 1.29
Capillaroscopy. Best Pract Res Clin Rheumatol (2008) 1.26
Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis. Ann N Y Acad Sci (2002) 1.25
Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep (2013) 1.25
Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev (2011) 1.25
Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med (2006) 1.24
Rheumatology education in Europe: results of a survey of young rheumatologists. Clin Exp Rheumatol (2011) 1.23
Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci (2006) 1.22
Atrophy/hypertrophy cell signaling in muscles of young athletes trained with vibrational-proprioceptive stimulation. Neurol Res (2011) 1.19
Home-based functional electrical stimulation rescues permanently denervated muscles in paraplegic patients with complete lower motor neuron lesion. Neurorehabil Neural Repair (2010) 1.17
Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? J Rheumatol (2005) 1.16
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis (2006) 1.16
Resistant Behçet disease responsive to anakinra. Ann Intern Med (2008) 1.15
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum (2011) 1.15
Use of glucocorticoids and risk of infections. Autoimmun Rev (2008) 1.15
OARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group. J Rheumatol (2011) 1.14
SLE diagnosis and treatment: when early is early. Autoimmun Rev (2010) 1.13
Disinfection of ocular cells and tissues by atmospheric-pressure cold plasma. PLoS One (2012) 1.12
Environment and systemic lupus erythematosus: an overview. Autoimmunity (2005) 1.12
A growing need for capillaroscopy in rheumatology. Arthritis Rheum (2009) 1.11
Anti-Mi-2 antibodies. Autoimmunity (2005) 1.10
Nailfold capillaroscopy for prediction of novel future severe organ involvement in systemic sclerosis. J Rheumatol (2013) 1.10
Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am J Cardiol (2006) 1.07
How to perform and interpret capillaroscopy. Best Pract Res Clin Rheumatol (2013) 1.07
Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med Wkly (2010) 1.06
Overlap connective tissue disease syndromes. Autoimmun Rev (2012) 1.05
Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J Rheumatol (2009) 1.05
Congenital heart block not associated with anti-Ro/La antibodies: comparison with anti-Ro/La-positive cases. J Rheumatol (2009) 1.05
The contribution of capillaroscopy to the differential diagnosis of connective autoimmune diseases. Best Pract Res Clin Rheumatol (2007) 1.04
Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) (2010) 1.04
Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. J Rheumatol (2003) 1.03
Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum (2010) 1.03
Circadian rhythms in rheumatology--a glucocorticoid perspective. Arthritis Res Ther (2014) 1.03
Does seronegative antiphospholipid syndrome really exist? Autoimmun Rev (2011) 1.03
Estrogens in pregnancy and systemic lupus erythematosus. Ann N Y Acad Sci (2006) 1.02
Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6. J Rheumatol (2002) 1.02
Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. Ann Rheum Dis (2010) 1.02
Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine (2010) 1.02
Capillarosecopic patterns in rheumatic diseases. Acta Reumatol Port (2007) 1.02
Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. PLoS One (2013) 1.01
Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod Toxicol (2006) 1.01
Sex hormone modulation of cell growth and apoptosis of the human monocytic/macrophage cell line. Arthritis Res Ther (2005) 1.00
Capillaroscopy. Best Pract Res Clin Rheumatol (2005) 0.99